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Background: Both high hyperdiploidy (HeH) and the translocation t(9;22)(q34;q11) are recurrent abnormalities in
childhood B-cell acute lymphoblastic leukemia (ALL) and both are used in current classification to define different
genetic and prognostic subtypes of the disease. The coexistence of these two primary genetic aberrations within
the same clone is very rare in children with ALL. Here we report a new case of a 17-year-old girl with newly
diagnosed ALL and uncommon cytogenetic and clinical finding combining high hyperdiploidy and a cryptic
BCR/ABL1 fusion and an inherited Charcot-Marie-Tooth neuropathy detected during the induction treatment.
Results: High hyperdiploid karyotype 51,XX,+X,+4,+14,+17,+21 without apparent structural aberrations was
detected by conventional cytogenetic analysis and multicolor FISH. A cryptic BCR/ABL1 fusion, which was caused by the
insertion of part of the ABL1 gene into the 22q11 region, was proved in HeH clone by FISH, RT-PCR and CGH-SNP array.
In addition, an abnormal FISH pattern previously described as the deletion of the 3′BCR region in some BCR/ABL1
positive cases was not proved in our patient.
Conclusion: A novel case of extremely rare childhood ALL, characterized by HeH and a cryptic BCR/ABL1 fusion, is
presented and to the best of our knowledge described for the first time. The insertion of ABL1 into the BCR region in
malignant cells is supposed. Clearly, further studies are needed to determine the genetic consequences and prognostic
implications of these unusual cases.
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Pediatric B-cell precursor acute lymphoblastic leukemia
(BCP-ALL) is a heterogeneous disease on both the cyto-
genetic and genetic levels [1]. A number of acquired
chromosomal aberrations have been identified in the bone
marrow cells of children with ALL, which provide diag-
nostic and prognostic information that directly affects
patient management [2].
The Philadelphia (Ph) chromosome, i.e., translocation
t(9;22)(q34;q11), giving rise to the BCR/ABL1 fusion
gene, is a rare finding in children with ALL, accounting
for ~3% of cases, and is traditionally associated with a
poor outcome [3]. However, implementation of tyrosine
kinase inhibitors to standard therapy greatly improved* Correspondence: libuse.lizcova@vfn.cz
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unless otherwise stated.the survival of children with Ph + ALL [4]. In a small
number of ALL patients, the Ph chromosome is not de-
tected by conventional cytogenetics, but the BCR/ABL1
fusion is present [5]. In these cases, the fusion either
arises as a cryptic rearrangement or is masked within a
complex karyotype and can only be detected by molecular
cytogenetic and/or molecular genetic methods. On the
contrary, high hyperdiploidy (HeH), defined as the pres-
ence of 51–67 chromosomes in the karyotype, is the most
frequent cytogenetic finding in childhood ALL, occurring
in 25%–30% of cases. It is characterized by a nonrandom
gain of specific chromosomes and a clinically favorable
prognosis [6,7].
Although HeH is a common finding in childhood ALL,
there are rare instances of high-hyperdiploid patients car-
rying other ALL-specific translocations, i.e., t(9;22)(q34;
q11), t(12;21)(p13;q22), t(1;19)(q23;p13), and MLL rear-
rangements. These cases comprise 1%–4% of the patients
with high-hyperdiploid ALL [8]. We present a patient withLtd. This is an Open Access article distributed under the terms of the Creative
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iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Lizcova et al. Molecular Cytogenetics 2014, 7:72 Page 2 of 5
http://www.molecularcytogenetics.org/content/7/1/72newly diagnosed ALL and a rare cytogenetic finding, com-
bining HeH and an unusual BCR/ABL1 fusion caused by
the insertion of part of the ABL1 gene into the 22q11 re-
gion. Moreover, the patient was diagnosed with an inher-
ited neuropathy Charcot-Marie-Tooth syndrome during
the antileukemic treatment.
Case presentation
A 17-year-old girl was diagnosed with common ALL
(cALL) in January 2013 after experiencing one month of
fatigue, bone pain at rest, and lymphocytosis in the periph-
eral blood (lymphocytes 86%). A complete blood count
showed 11.3 × 109/L WBC, 86 g/L hemoglobin, and a
platelet count of 42 × 109/L. Her bone marrow was infil-
trated by lymphoblasts (96.8%) with an L1 morphology.
Blasts had hyperdiploid DNA content (DNA index 1.089).
Immunophenotypically blasts corresponded to cALL with
aberrant expression of CD66c, high CD34 positivity and
low expression of CD38 antigen. Immunophenotype was
typical for BCR/ABL1 positivity [9]. BCR/ABL fusion gene
was confirmed with multiplex RT-PCR.
The patient has been treated according to the
EsPhALL 2010 protocol for BCR/ABL-positive ALL with
a combination of chemotherapy and imatinib (Glivec).
During induction, the patient developed very severe per-
ipheral neurotoxicity with quadriparesis and paralytic
ileus, which required major surgery with stoma. This
critical clinical condition resulted in interruption of the
chemotherapy treatment for two weeks. Surprisingly, the
cause of this unexpected complication was inherited
neuropathy Charcot-Marie-Tooth syndrome (CMT1A
subtype), with a proven PMP22 mutation. Subsequently
it was clear that the neurotoxicity was an abnormal reac-
tion to Vincristine therapy and therefore further vinca
alkaloid medication was contraindicated. At present, the
patient is in continuous complete remission (18 months
from the diagnosis) on maintenance chemotherapy with
imatinib, she is after submerging of her stoma and her
neurological status is improving.
For the cytogenetic analyses, bone marrow cells were
cultured for 24 hours without stimulation, and chromo-
somal preparations were made using standard techniques.
In total, 25 metaphases were analyzed and the karyotypes
were described according to An International System for
Human Cytogenetic Nomenclature (ISCN 2013) [10].
To detect the BCR/ABL1 fusion gene, fluorescence in
situ hybridization (FISH) was performed with commer-
cially available locus-specific probes (Vysis LSI BCR/ABL
Dual Color Dual Fusion Translocation Probe and Vysis
LSI BCR/ABL ES Dual Color Translocation Probe; Abbott
Molecular, Des Plaines, IL, USA). All available metaphases
and 200 interphase nuclei were analyzed.
Other chromosomal aberrations were analyzed with
multicolor FISH (mFISH) and comparative genomichybridization based array (aCGH) using the 24XCyte
color kit (MetaSystems, Altlussheim, Germany) and an
oligonucleotide CGH–single-nucleotide polymorphism
(SNP) array (BlueGnome, Cambridge, UK) respectively.
Array results were confirmed by FISH with the appro-
priate bacterial artificial chromosome (BAC) probes
(BlueGnome). All techniques were done according to
manufacturer’s recommendations.
The fusion transcript BCR/ABL1 was detected with re-
verse transcription–polymerase chain reaction (RT–PCR),
which was performed according to Europe Against Cancer
program protocol [11]. The amount of cDNA was normal-
ized to the expression of housekeeping gene GUS as de-
scribed previously [12].
An m-BCR/ABL1 fusion gene was detected with multi-
plex RT–PCR. Moreover, we found also the genomic
breakpoint between the BCR and ABL1 genes (BCR in-
tron 1/ABL1 intron 1). The karyotype was described as
follows: 51,XX,+X,+4,+14,+17,+21[22]/46,XX[3]. How-
ever, FISH with the BCR/ABL Extra Signal and BCR/
ABL Dual Fusion Probes detected the BCR/ABL1 fusion
with an abnormal FISH signal pattern (1F2O1G), con-
sistent with a breakpoint within m-BCR and the loss of
the 3′BCR signal from der(9) in ten out of eleven meta-
phases and ~70% of the interphase nuclei (Figure 1). A
detailed FISH signal analysis of the abnormal meta-
phases revealed the fusion signal to be located on appar-
ently normal chromosome 22 and the ABL1 signal in the
9q34 region of two copies of chromosome 9. The ex-
pected deletion of the 3′BCR region (from the FISH re-
sults) was not detected by array CGH and BAC probes
and only other chromosomal abnormalities were found,
including trisomies of chromosomes X, 4, 14, 17, and 21,
cryptic deletion of the short arm of chromosome 20 [del
(20) (p12.1p12.1)] and submicroscopic amplification of
the 22q11.22 region (Figure 1).
Based on the cytogenetic and genetic results, it is clear
that the BCR/ABL1 fusion in our patient arose from the
submicroscopic insertion of part of the ABL1 gene into
chromosome 22. It is based on the facts that: (1) no clas-
sical or variant Ph translocation was detected by conven-
tional cytogenetic/mFISH; (2) loss of the 3′BCR region,
although expected from interphase FISH signal pattern,
was not confirmed by array CGH or by FISH with BAC
probes for this region, i.e. entire BCR signal remained
on chromosome 22 and was not translocated on
chromosome 9; and (3) only the BCR/ABL1 fusion was
proved at the RNA as well as DNA level, while the re-
ciprocal ABL1/BCR fusion was not found by any of
these approaches.
Our results show that only parallel cytogenetic, molecu-
lar cytogenetic, and molecular genetic analyses can pro-
vide detailed information about cryptic and prognostically
significant aberrations that could not have been achieved
EA
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Figure 1 Results of molecular cytogenetic analysis. Multicolor FISH (A) and array CGH (B) showing trisomies of chromosomes X, 4, 14, 17 and
21 (A, B) and submicroscopic aberrations: deletion of chromosome 20 and amplification of chromosome 22 (B). BCR/ABL1 positive metaphase
hybridized with BCR/ABL dual fusion (DF) probe demonstrating apparent loss of green 3′BCR signal, i.e. 1F2O1G FISH pattern (caused by the insertion of
the ABL1 gene into the BCR region, thus entire BCR signal remained on chromosome 22) (C). FISH with BAC probes RP11-80O7 (orange) and RP11-400P21
(green) with evidence of normal finding of 22q11.23 region matching to 3′BCR locus (two orange signals) and deletion of 20p12.1 (one green signal)
(D). Detailed view of array CGH result of chromosome 22 showing amplification of the 22q11.22 region and normal 22q11.23 region pattern (E).
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metaphase FISH results were important for the correct in-
terpretation of the interphase FISH findings, because only
this analysis could identify the location of the BCR/ABL1
fusion on der(22). The current inclusion of array techniques
into routine practice could lead us to reevaluate the real oc-
currence of deletions of either the 3′BCR or 5′ABL1 region
in BCR/ABL1-positive cases (especially with cryptic inser-
tions) previously described by FISH analyses.
Several patients with CML, or less frequently with ALL,
have been reported with cryptic insertions of part of the
BCR region into ABL1 at 9q34 or rarely of ABL1 into BCR
at 22q11 [13,14]. However, to our knowledge, this is the
first published case of such an aberration in childhood
high-hyperdiploid ALL with inherited Charcot-Marie-
Tooth neuropathy. In general, ALL-specific rearrange-
ments are extremely rare in patients with HeH and it is
difficult to identify the primary abnormality. In most cases(as in our patient), both aberrations were presented simul-
taneously in abnormal cells. However, few cases of HeH
Ph-positive ALL have been published in the literature
[15,16], and these patients displayed not only a Ph-positive
HeH clone, but also cells with 46 chromosomes and t(9;22)
(q34;q11) as the sole abnormality, suggesting that the Ph
chromosome was the primary aberration.
There is no difference in the gain of specific chromo-
somes (namely X, 4, 6, 8, 10, 14, 17, 18 a 21) between
patients with high-hyperdiploid ALL and commonly en-
countered ALL aberrations, and those with high-
hyperdiploid ALL. The only exception is the trisomy of
chromosome 2, which was previously described as a
quite frequent chromosome gain in patients with trans-
location t(9;22)(q34;q11) [6,16]. However, trisomy of
chromosome 2 was not found in our patient, nor was
revealed as a frequent trisomy in six other currently de-
scribed cases with Ph positive HeH ALL [8].
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known translocations are considered to represent a bio-
logically distinct subgroup, which may have independent
prognostic implications [17]. From previously reported
cases, it seems that the prognostic impact of the transloca-
tion could override the beneficial effect of HeH [17,18].
However, brief follow-up period does not allow to assess
any conclusion about the impact of this finding on prog-
nosis in our patient nor to predict the effect of the inher-
ited neuropathy.
Conclusion
In conclusion, a novel case of extremely rare childhood
ALL, characterized by HeH and a cryptic BCR/ABL1 fu-
sion, is presented and described for the first time and the
insertion of ABL1 into the BCR region in malignant cells
is supposed. Although several cases of childhood ALL with
HeH and general ALL-specific aberrations have been pub-
lished, the exact pathogenetic mechanisms of the disease
in these patients have not been clarified. Clearly, further
studies of these uncommon cases are necessary to deter-
mine the genetic consequences and real prognostic impli-
cations of these phenomena.
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